Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Samsung Bioepis

Request full access

A biopharmaceutical company committed to realizing healthcare that is accessible to everyone

Incheon, South KoreaFounded 1938Biotech & Life Sciences

About Samsung Bioepis

What if a technology giant known for phones and TVs decided to tackle one of the biggest challenges in healthcare: the soaring cost of biologic medicines? In 2012, Samsung Group did just that, establishing Samsung Bioepis as a joint venture with the American biotech firm, Biogen. Spearheaded by its first CEO, Christopher Ko, the mission was clear: develop and produce high-quality biosimilars to increase patient access to life-altering treatments. The company was founded in Incheon, South Korea, as a strategic partnership. Samsung brought its world-class manufacturing expertise, while Biogen provided deep biopharmaceutical experience and an initial investment. This combination allowed Samsung Bioepis to quickly build a robust pipeline of biosimilar candidates targeting major diseases in immunology, oncology, and ophthalmology. They focused on creating more affordable versions of complex, expensive biologic drugs, aiming to drive down healthcare costs and expand treatment options globally. The playbook worked. By partnering with major pharmaceutical companies like Biogen and Organon for commercialization, Samsung Bioepis gained access to extensive global sales and marketing networks. A pivotal moment arrived in 2022 when Samsung Biologics, the parent company, acquired Biogen's entire stake for $2.3 billion, making Samsung Bioepis a wholly owned subsidiary. This move granted the company greater autonomy and agility in its business operations. Today, Samsung Bioepis stands as a key player in the global biosimilar market, having successfully brought numerous products to patients worldwide and achieving record revenues.

Source: Dealroom company data

At a glance

Status
Operational
Employees
697
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma
Client focus
B2B
Investment activity
3 companies, latest Mar 2026
Capital deployed
$0
Preferred round
POST IPO CONVERTIBLE

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Jun 2018 $628M $2.5B Biogen —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Samsung Bioepis website traffic

Latest recorded traffic for Samsung Bioepis is 25K monthly website visits, up 509.8% over the last three months. Samsung Bioepis's team grew 0% over the past year.

Latest monthly visits25K 3-month web change+509.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Samsung Bioepis in the Incheon ecosystem

Live from Dealroom

The Samsung Bioepis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Biogen
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇰🇷 South Korea · Incheon HQ
Book a demo for the full country breakdown

See Samsung Bioepis’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.